Additional file 1 of Novel pathological predictive factors for extranodal extension in oral squamous cell carcinoma: a retrospective cohort study based on tumor budding, desmoplastic reaction, tumor-infiltrating lymphocytes, and depth of invasion

Additional file 1: Clinicopathological status of 186 surgically resected specimens. Supplementary Table 1. The clinicopathological features were evaluated as follows; Sex (0: female; 1: male); cDOI 5 mm (0: ≤5 mm; 1: <5 mm); cDOI 10 mm (0: ≤10 mm; 1: DOI >10 mm); pDOI 5 mm (0: ≤5 mm; 1: <5 mm); pDOI 10 mm (0: ≤10 mm; 1: DOI >10 mm); Metastasis (0: absence; 1: presence); Number of lymph node metastases (0: n=0; 1: n=1; 2: n≥2); Pattern of invasion (1: pattern of 1 and 2; 2: pattern of 3 and 4); LyV (0: absence; 1: presence); pT (0: pT1, 2; 1: pT3, 4); pN (0: no LN metastasis; 1: pN1; 2: pN2 and 3); ENE (0: absence; 1: presence); DR (0: DR-M; 1: DR-I); TB (0: TB-L; 1: TB-H); TILs (0: TILs-L; 1: TILs-H); TB-H/pDOI>10 mm (0: no; 1: yes); DR-I/TILs-L (0: no; 1: yes); DR-I/TILs-L/pDOI >10 mm (0: no; 1: yes). MRI and CT were used in measuring the cDOI. Each unknown mass and artifact indicates that MRI could not detect a mass due to the small size, superficial location, or artifact. cDOI, clinical depth of invasion; pDOI, pathological depth of invasion; pT, pathological T; pN, pathological N; ENE, extranodal extension; LyV, lymphovascular invasion; DR, desmoplastic reaction; TB, tumor budding; TILs, tumor-infiltrating lymphocytes; TB-H, high tumor budding; DR-I, immature desmoplastic reaction; TILs-L, low-grade tumor-infiltrating lymphocytes; MRI, magnetic resonance imaging; CT, computed tomography.

附加文件1：186例手术切除标本的临床病理信息。补充表1。
本研究对以下临床病理特征进行评估：性别（0：女性；1：男性）；临床浸润深度（clinical depth of invasion, cDOI）5mm亚组（0：≤5mm；1：<5mm）；临床浸润深度（cDOI）10mm亚组（0：≤10mm；1：浸润深度>10mm）；病理浸润深度（pathological depth of invasion, pDOI）5mm亚组（0：≤5mm；1：<5mm）；病理浸润深度（pDOI）10mm亚组（0：≤10mm；1：浸润深度>10mm）；转移（0：无；1：有）；淋巴结转移数目（0：n=0；1：n=1；2：n≥2）；浸润模式（1：模式1与模式2；2：模式3与模式4）；淋巴血管侵犯（lymphovascular invasion, LyV）（0：无；1：有）；病理T分期（pathological T, pT）（0：pT1、pT2；1：pT3、pT4）；病理N分期（pathological N, pN）（0：无淋巴结转移；1：pN1；2：pN2和pN3）；淋巴结外侵犯（extranodal extension, ENE）（0：无；1：有）；促纤维组织增生反应（desmoplastic reaction, DR）（0：DR-M；1：DR-I）；肿瘤出芽（tumor budding, TB）（0：TB-L；1：TB-H）；肿瘤浸润淋巴细胞（tumor-infiltrating lymphocytes, TILs）（0：TILs-L；1：TILs-H）；高肿瘤出芽/病理浸润深度>10mm（0：否；1：是）；未成熟促纤维组织增生反应/低级别肿瘤浸润淋巴细胞（0：否；1：是）；未成熟促纤维组织增生反应/低级别肿瘤浸润淋巴细胞/病理浸润深度>10mm（0：否；1：是）。
采用磁共振成像（magnetic resonance imaging, MRI）与计算机断层扫描（computed tomography, CT）测量临床浸润深度（cDOI）。若出现不明肿物或伪影，则提示因病灶体积过小、位置表浅或存在伪影，磁共振成像无法检测到肿物。
本研究涉及的缩写术语释义如下：cDOI为临床浸润深度（clinical depth of invasion）；pDOI为病理浸润深度（pathological depth of invasion）；pT为病理T分期（pathological T）；pN为病理N分期（pathological N）；ENE为淋巴结外侵犯（extranodal extension）；LyV为淋巴血管侵犯（lymphovascular invasion）；DR为促纤维组织增生反应（desmoplastic reaction）；TB为肿瘤出芽（tumor budding）；TILs为肿瘤浸润淋巴细胞（tumor-infiltrating lymphocytes）；TB-H为高肿瘤出芽（high tumor budding）；DR-I为未成熟促纤维组织增生反应（immature desmoplastic reaction）；TILs-L为低级别肿瘤浸润淋巴细胞（low-grade tumor-infiltrating lymphocytes）；MRI为磁共振成像（magnetic resonance imaging）；CT为计算机断层扫描（computed tomography）。